The Market Shift Most Telehealth Brands Are Missing
Most telehealth founders see “12 peptides under review” and think: more SKUs, more revenue, more growth.
That’s not how this plays out.
When the U.S. Food and Drug Administration increases scrutiny or clarifies pathways around a category like peptides, it doesn’t just affect access. It compresses timelines. It standardizes expectations. And most importantly, it invites competition.
We’ve seen this exact pattern before. When GLP-1 demand accelerated between 2022 and 2025, telehealth brands initially saw CACs as low as $80–$150. Within 12–18 months, as more providers, clinics, and DTC brands entered the space, those same acquisition costs pushed into the $250–$600 range depending on channel and geography.
At the same time, conversion rates didn’t improve. In fact, across 20+ telehealth funnels we reviewed internally in 2025, the average landing page conversion rate sat between 1.8% and 3.2%, with only a handful of brands breaking past 8–10%.
That gap is what kills profitability.
Because when CAC doubles and conversion stays flat, your margin doesn’t shrink slightly. It disappears.
So no, this isn’t just a peptide story. It’s a market dynamics story.
What Actually Happens When Access Expands
Peptides have been stuck in a fragmented middle ground for years. Some providers offered them, others avoided them entirely, and patient understanding was inconsistent at best. That friction slowed adoption.
If regulatory clarity improves even slightly, adoption doesn’t grow linearly. It spikes.
Here’s what typically follows within the first 6–12 months of expanded access:
- Supply increases faster than demand
New clinics, telehealth startups, and hybrid providers enter quickly. In GLP-1, we saw a surge of hundreds of new advertisers on Meta within a single quarter - Paid channels saturate
CPMs rise as more brands compete for the same audience. In health categories, CPM increases of 20–40% YoY are common once a category heats up. - Consumer confusion increases
More options don’t make decisions easier. They make them harder. When users see five similar peptide offers with slightly different claims, they don’t convert faster. They hesitate. - Price becomes easier to compare
When differentiation is weak, users default to price. That compresses margins across the category.
This is exactly what happened in telehealth. Early operators grew fast because demand outpaced supply. Later entrants had to fight for attention, trust, and conversion in a much noisier market.
Peptides are setting up the same way, just earlier in the cycle.
Where Most Brands Will Misread This Moment
The default move is predictable -
Launch peptide-specific landing pages.
Add new product lines.
Increase ad spend to “capture demand early.”
On paper, that looks like speed. In reality, it’s misalignment. Adding products doesn’t solve weak positioning - it exposes it.
If a user lands on your site today and can’t immediately answer three questions what this is, who it’s for, and why they should trust you, adding peptides won’t fix that. It just adds another layer of decision-making.
We’ve seen brands increase bounce rates by 15–25% simply by expanding their navigation and product options without tightening their messaging. More choice without more clarity reduces conversion every time.
The Real Constraint Isn’t Supply. It’s Trust.
As categories mature, the bottleneck shifts.
Early on, the constraint is access. Can you even get the treatment? Later, the constraint becomes trust. Who do you choose? This is where most telehealth brands fall behind. They optimize for availability instead of understanding.
But the data is clear:
- 70%+ of health consumers say they need to “fully understand a treatment” before purchasing (Pew Research)
- Over 60% of users abandon healthcare forms due to complexity or lack of clarity mid-process
- Brands that include clear expectations and timelines in their onboarding flows see up to 20–30% higher completion rates
In other words, the brand that explains better converts better, not the one with the most products.
What Actually Drives Growth in This Phase
1. Clear Positioning Beats Broad Offerings
When everything looks similar, specificity wins.
The highest-converting telehealth brands don’t try to serve everyone. They narrow their message until it’s obvious who the product is for.
Instead of offering “peptides for health optimization,” they anchor around a single outcome:
- Weight loss for women over 40
- Cognitive support for high-performance professionals
- Recovery protocols for athletes
That level of clarity reduces cognitive load and increases conversion. In tests we’ve run, narrowing the target audience and rewriting messaging accordingly improved conversion rates by 30–60% without any change in traffic.
2. Conversion Rate Becomes the Primary Lever
Most brands still treat traffic as the growth engine.
It’s not.
Conversion is.
If you’re paying $60 per click and converting at 2%, you’re acquiring customers at $3,000. If you increase conversion to 6%, that drops to $1,000 without touching your ad spend.
That’s the difference between scaling and stalling.
Across telehealth funnels, the biggest leaks are consistent:
- 40–60% of users bounce on the landing page
- 30–50% abandon intake forms midway
- 10–20% don’t complete payment after consult
Each step compounds inefficiency.
Fixing even one of these stages has more impact than increasing traffic by 50%.
3. Education Is the New Acquisition Channel
Peptides are still poorly understood by the average consumer.
That’s not a disadvantage. It’s leverage.
Brands that invest in explaining:
- What the peptide does
- What results actually look like over time
- What risks or limitations exist
consistently outperform those that rely on vague claims.
We’ve seen educational landing pages outperform product-first pages by 20–35% in conversion rate when the category is complex or unfamiliar.
Clarity reduces hesitation. And hesitation is what kills conversion.
4. Retention Determines Whether You Survive Rising CAC
Acquisition gets harder as competition increases. That’s predictable.
What’s less discussed is how retention offsets that.
In subscription-based telehealth models, a 20% increase in retention can improve LTV by 30–50%. That gives you more room to absorb rising CAC without sacrificing profitability.
But most brands don’t build for this.
They focus on the first purchase, then lose the customer due to lack of guidance, unclear expectations, or poor follow-up.
The brands that scale in competitive markets don’t just acquire users. They manage the experience after the sale.
What This Means Going Into 2026
This isn’t a slow shift. It’s already happening.
Telehealth continues to grow at an estimated 20–25% annually, and peptides are adding another layer of competition on top of that growth.
As access expands, expect three things to happen simultaneously:
- Acquisition costs increase across paid channels
- Conversion rates become the primary constraint on growth
- Brand trust becomes the deciding factor in purchase decisions
That combination creates pressure.
Brands that relied on early demand or simple funnels won’t hold performance.
Brands that invest in clarity, conversion, and retention will.
Bottom Line
The FDA reviewing peptides isn’t just a regulatory update.
It’s a signal that this category is about to get more competitive, more crowded, and less forgiving.
More brands will enter.
More offers will look the same.
More pressure will be placed on performance.
The brands that win won’t be the ones that move the fastest or launch the most products.
They’ll be the ones that make the clearest case for why they should be chosen, convert efficiently at every stage of the funnel, and build enough trust to keep customers long after the first purchase.
